Glaucoma Surgical Procedures - (0035)
Defines medical necessity, investigational status, and coding for glaucoma surgical procedures including aqueous shunts/drainage devices, XEN gel stent, iStent Infinite, canaloplasty (ab externo or ab interno), and lists procedures considered experimental/unproven. Applies to Cigna-administered benefit plans.
Focused review (10/15/2024) removed policy statements for several MIGS devices/procedures (Glaukos iStent, iStent Inject, Ivantis Hydrus, ab interno suprachoroidal microstent, drug-eluting ocular devices, goniotomy/trabeculotomy ab interno, and excimer laser trabeculostomy).
Annual review dated 4/15/2026: No clinical policy statement changes.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.